Your browser doesn't support javascript.
loading
Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells.
Wallis, Nadav; Oberman, Froma; Shurrush, Khriesto; Germain, Nicolas; Greenwald, Gila; Gershon, Tehila; Pearl, Talia; Abis, Giancarlo; Singh, Vikash; Singh, Amandeep; Sharma, Arun K; Barr, Haim M; Ramos, Andres; Spiegelman, Vladimir S; Yisraeli, Joel K.
Afiliação
  • Wallis N; Department of Developmental Biology and Cancer Research, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Oberman F; Department of Developmental Biology and Cancer Research, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Shurrush K; The Wohl Drug Discovery Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.
  • Germain N; The Wohl Drug Discovery Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.
  • Greenwald G; Department of Developmental Biology and Cancer Research, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Gershon T; Department of Developmental Biology and Cancer Research, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Pearl T; Department of Developmental Biology and Cancer Research, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Abis G; Division of Biosciences, Institute of Structural and Molecular Biology, University College London, London, UK.
  • Singh V; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Pennsylvania State University, College of Medicine, Hershey, PA, USA.
  • Singh A; Department of Pharmacology, Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA, USA.
  • Sharma AK; Department of Pharmacology, Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA, USA.
  • Barr HM; The Wohl Drug Discovery Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.
  • Ramos A; Division of Biosciences, Institute of Structural and Molecular Biology, University College London, London, UK.
  • Spiegelman VS; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Pennsylvania State University, College of Medicine, Hershey, PA, USA.
  • Yisraeli JK; Department of Developmental Biology and Cancer Research, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
RNA Biol ; 19(1): 26-43, 2022.
Article em En | MEDLINE | ID: mdl-34895045
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Proteínas de Ligação a RNA / Carcinogênese / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Proteínas de Ligação a RNA / Carcinogênese / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article